Summary
Testing a cheaper way to do clinical research, Pfizer ($PFE) has stumbled in a journey to complete what's been called the first completely virtual clinical trial. But the drug giant has fixed some of the bugs in the study and is expanding the pioneering trial from the U.S. to Europe.
Description
Pfizer isn't the only outfit traveling the virtual trial road. In January New York-based drug developer Transparency Life Sciences unveiled its plans to take the virtual strategy even further than Pfizer, using online crowdsourcing to gather feedback from clinicians on the design of virtual trials that the company plans to conduct.